MX2012007671A - Agente terapeutico (y-39983) para la disfuncion endotelial de la cornea. - Google Patents
Agente terapeutico (y-39983) para la disfuncion endotelial de la cornea.Info
- Publication number
- MX2012007671A MX2012007671A MX2012007671A MX2012007671A MX2012007671A MX 2012007671 A MX2012007671 A MX 2012007671A MX 2012007671 A MX2012007671 A MX 2012007671A MX 2012007671 A MX2012007671 A MX 2012007671A MX 2012007671 A MX2012007671 A MX 2012007671A
- Authority
- MX
- Mexico
- Prior art keywords
- corneal endothelial
- endothelial cells
- compound
- therapeutic agent
- agent
- Prior art date
Links
- 206010048554 Endothelial dysfunction Diseases 0.000 title abstract 2
- 239000003814 drug Substances 0.000 title abstract 2
- 230000008694 endothelial dysfunction Effects 0.000 title abstract 2
- 229940124597 therapeutic agent Drugs 0.000 title abstract 2
- 210000000399 corneal endothelial cell Anatomy 0.000 abstract 5
- 150000001875 compounds Chemical class 0.000 abstract 3
- 239000003795 chemical substances by application Substances 0.000 abstract 2
- 230000003511 endothelial effect Effects 0.000 abstract 2
- 239000001963 growth medium Substances 0.000 abstract 2
- 230000001737 promoting effect Effects 0.000 abstract 2
- 125000000339 4-pyridyl group Chemical group N1=C([H])C([H])=C([*])C([H])=C1[H] 0.000 abstract 1
- 239000004480 active ingredient Substances 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 239000007943 implant Substances 0.000 abstract 1
- 238000001727 in vivo Methods 0.000 abstract 1
- 238000004519 manufacturing process Methods 0.000 abstract 1
- 230000002062 proliferating effect Effects 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0048—Eye, e.g. artificial tears
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0618—Cells of the nervous system
- C12N5/0621—Eye cells, e.g. cornea, iris pigmented cells
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/999—Small molecules not provided for elsewhere
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Biomedical Technology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Ophthalmology & Optometry (AREA)
- Genetics & Genomics (AREA)
- Biotechnology (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Microbiology (AREA)
- Cell Biology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biochemistry (AREA)
- General Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Materials For Medical Uses (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2009299180 | 2009-12-29 | ||
| PCT/JP2010/071424 WO2011080984A1 (en) | 2009-12-29 | 2010-11-24 | Therapeutic agent (y - 39983 ) for corneal endothelial dysfunction |
| PCT/JP2010/073904 WO2011081221A1 (en) | 2009-12-29 | 2010-12-28 | Therapeutic agent (y - 39983 ) for corneal endothelial dysfunction |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2012007671A true MX2012007671A (es) | 2012-08-23 |
Family
ID=43598277
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2012007671A MX2012007671A (es) | 2009-12-29 | 2010-12-28 | Agente terapeutico (y-39983) para la disfuncion endotelial de la cornea. |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US20120288482A1 (cg-RX-API-DMAC10.html) |
| EP (1) | EP2519237A1 (cg-RX-API-DMAC10.html) |
| JP (2) | JP5750444B2 (cg-RX-API-DMAC10.html) |
| KR (1) | KR20120099147A (cg-RX-API-DMAC10.html) |
| CN (1) | CN102770136A (cg-RX-API-DMAC10.html) |
| BR (1) | BR112012016128A8 (cg-RX-API-DMAC10.html) |
| CA (1) | CA2785851A1 (cg-RX-API-DMAC10.html) |
| MX (1) | MX2012007671A (cg-RX-API-DMAC10.html) |
| RU (1) | RU2563141C2 (cg-RX-API-DMAC10.html) |
| WO (2) | WO2011080984A1 (cg-RX-API-DMAC10.html) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TR201903889T4 (tr) * | 2011-12-06 | 2019-04-22 | Astellas Inst For Regenerative Medicine | Korneal endotelyal hücreler üreten yönlendirilmiş diferansiyasyona yönelik yöntem. |
| BR112016011096A2 (pt) | 2013-11-27 | 2017-09-19 | Kyoto Prefectural Public Univ Corp | Aplicação de laminina à cultura de célula endotelial da córnea |
| US10959997B2 (en) | 2013-12-27 | 2021-03-30 | Kyoto Prefectural Public University Corporation | Combined agent for cell therapy of corneal endothelial cell |
| CN106604730B (zh) * | 2014-09-24 | 2019-12-20 | 兴和株式会社 | 角膜厚度调节剂 |
| MX387839B (es) * | 2014-10-31 | 2025-03-04 | Senju Pharma Co | Laminina para usarse en el tratamiento de una enfermedad, un trastorno o una afección de un endotelio de córnea. |
| JP6770435B2 (ja) | 2014-10-31 | 2020-10-14 | 京都府公立大学法人 | ラミニンによる網膜および神経の新規治療 |
| EP3416658B1 (en) * | 2016-02-15 | 2023-03-22 | Kyoto Prefectural Public University Corporation | Human functional corneal endothelial cell and application thereof |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1195372A1 (en) | 1994-04-18 | 2002-04-10 | Mitsubishi Pharma Corporation | N-heterocyclic substituted benzamide derivatives with antihypertensive activity |
| CA2443918C (en) | 2001-04-11 | 2012-06-05 | Senju Pharmaceutical Co., Ltd. | Visual function disorder improving agents containing rho kinase inhibitors |
| JP2004024852A (ja) | 2002-04-30 | 2004-01-29 | Amniotec:Kk | 角膜内皮様シート、及びその作製方法 |
| US7087237B2 (en) * | 2003-09-19 | 2006-08-08 | Advanced Ocular Systems Limited | Ocular solutions |
| EP1752456B1 (en) * | 2004-06-03 | 2015-08-26 | Senju Pharmaceutical Co., Ltd. | Corneal perception recovery drug containing amide compound |
| WO2006057270A1 (ja) * | 2004-11-26 | 2006-06-01 | Asahi Kasei Pharma Corporation | 含窒素３環化合物 |
| JP4766653B2 (ja) * | 2005-01-28 | 2011-09-07 | 株式会社林原生物化学研究所 | 眼科用医薬組成物 |
| WO2006095844A1 (ja) * | 2005-03-10 | 2006-09-14 | Mitsubishi Pharma Corporation | 医薬製剤 |
| WO2007083685A1 (ja) * | 2006-01-19 | 2007-07-26 | Senju Pharmaceutical Co., Ltd. | 生体内で細胞増殖可能な角膜内皮製剤 |
| WO2008016016A1 (fr) * | 2006-07-31 | 2008-02-07 | Senju Pharmaceutical Co., Ltd. | Préparation liquide aqueuse contenant un amide |
| KR20240045364A (ko) | 2007-08-29 | 2024-04-05 | 센주 세이야꾸 가부시키가이샤 | 각막 내피 세포 접착 촉진제 |
| JP5251632B2 (ja) | 2008-05-13 | 2013-07-31 | 新日鐵住金株式会社 | 耐遅れ破壊特性に優れた高強度鋼材、高強度ボルト及びその製造方法 |
| JP2010071424A (ja) | 2008-09-19 | 2010-04-02 | Toyota Motor Corp | 変速機の制御装置 |
-
2010
- 2010-11-24 WO PCT/JP2010/071424 patent/WO2011080984A1/en not_active Ceased
- 2010-12-28 WO PCT/JP2010/073904 patent/WO2011081221A1/en not_active Ceased
- 2010-12-28 KR KR1020127019919A patent/KR20120099147A/ko not_active Abandoned
- 2010-12-28 RU RU2012132443/15A patent/RU2563141C2/ru not_active IP Right Cessation
- 2010-12-28 CA CA2785851A patent/CA2785851A1/en not_active Abandoned
- 2010-12-28 CN CN2010800649229A patent/CN102770136A/zh active Pending
- 2010-12-28 BR BR112012016128A patent/BR112012016128A8/pt not_active IP Right Cessation
- 2010-12-28 US US13/519,682 patent/US20120288482A1/en not_active Abandoned
- 2010-12-28 JP JP2012530000A patent/JP5750444B2/ja not_active Expired - Fee Related
- 2010-12-28 MX MX2012007671A patent/MX2012007671A/es active IP Right Grant
- 2010-12-28 EP EP10805660A patent/EP2519237A1/en not_active Withdrawn
-
2015
- 2015-05-18 JP JP2015100969A patent/JP2015155460A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| RU2563141C2 (ru) | 2015-09-20 |
| JP2013515676A (ja) | 2013-05-09 |
| EP2519237A1 (en) | 2012-11-07 |
| BR112012016128A2 (pt) | 2016-05-31 |
| WO2011080984A1 (en) | 2011-07-07 |
| BR112012016128A8 (pt) | 2017-12-05 |
| CA2785851A1 (en) | 2011-07-07 |
| JP2015155460A (ja) | 2015-08-27 |
| US20120288482A1 (en) | 2012-11-15 |
| KR20120099147A (ko) | 2012-09-06 |
| RU2012132443A (ru) | 2014-02-10 |
| CN102770136A (zh) | 2012-11-07 |
| JP5750444B2 (ja) | 2015-07-22 |
| WO2011081221A1 (en) | 2011-07-07 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AU2011201462B2 (en) | Method of Administering Pirfenidone Therapy | |
| NZ597059A (en) | Inhibitors of influenza viruses replication | |
| SA515360229B1 (ar) | مثبطات عامل التمايز والنمو 8 | |
| NO20091548L (no) | Imidazolon- og imidazolidinonderivater som 11B-HSD1 inhibitorer for diabetes | |
| MX2012000414A (es) | Derivados piridin-4-ilo. | |
| CA2785851A1 (en) | Therapeutic agent (y - 39983 ) for corneal endothelial dysfunction | |
| NO20073959L (no) | Kinazolinderivat, fremgangsmate for fremstilling og anvendelse derav for inhibering av vekst av kreftceller | |
| SG151260A1 (en) | 5-substituted-2-phenylamino-benzamides as mek inhibitors | |
| WO2009134866A3 (en) | Cell membrane engineering | |
| MX2011008389A (es) | Sal de tipo tosilato de un derivado de 5-pirazolil-2-piridona, util en el tratamiento de la enfermedad pulmonar obstructiva cronica (epoc). | |
| NO20071617L (no) | Indozolonderivater som 11B-HSD1-inhibitorer | |
| IL219861A0 (en) | Process for preparing methyl {4,6-diamino-2-[1-(2-fluorobenzyl)-1h-pyrazolo[3,4-b]pyridin-3-yl]pyrimidin-5-yl}carbamate and its purification for use as pharmaceutically active compound | |
| PT2432760E (pt) | Derivados de espiro [2,4] heptano ligados em ponte como agonistas do receptor fprl2 e/ou receptor alx | |
| MX2010009395A (es) | Agonistas de receptores muscarinicos, composiciones, metodos de tratamiento de los mismos, y procesos para preparacion de los mismos. | |
| MX2009009238A (es) | Nuevos inhibidores de fosfodiesterasa. | |
| WO2008056368A3 (en) | Use of ex-vivo cultured hematopoietic cells for treatment of peripheral vascular diseases | |
| MX2009010165A (es) | Nuevas imidazo[4,5-b]piridina-7-carboxamidas 704. | |
| MX368157B (es) | Formulaciones de sal de meglumina del acido 1-(5,6-dicloro-1h-benz o[d]imidazol-2-il)-1h-pirazol-4-carboxilico. | |
| SG179207A1 (en) | Methods for preparing pyrimidine derivatives useful as protein kinase inhibitors | |
| WO2012020412A3 (en) | Fibrin based scaffold, preparation and use thereof | |
| TW200942529A (en) | Pyrrolidinyl derivatives and uses thereof | |
| WO2011025167A3 (ko) | 2, 6-위치가 치환된 3-니트로피리딘 유도체 화합물 또는 이의 약제학적으로 허용 가능한 염을 포함하는 암 예방 또는 치료용 약학 조성물 | |
| JP2013515676A5 (cg-RX-API-DMAC10.html) | ||
| MX2010009756A (es) | Agonistas de receptores muscarinicos, composiciones, metodos de tratamiento de los mismos, y proceso para preparacion de los mismos. | |
| IL209270A (en) | Compounds containing tricyclic nitrogen and their use as antibacterial |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| GB | Transfer or rights |
Owner name: SENJU PHARMACEUTICAL CO., LTD. |
|
| FG | Grant or registration |